Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04578392 · ClinicalTrials.gov registry record · NA

MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

A NA study of Crohn Disease, sponsored by The Cleveland Clinic.

Recruiting
Registry status
NA
Development phase
181
Enrollment target
7
Study locations

NCT04578392: Recruiting NA study of Crohn Disease, sponsored by The Cleveland Clinic.

NCT04578392 is a NA study of Crohn Disease that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 181 participants, below the 203-participant average among 71 other Crohn Disease trials with a reported enrollment target (11% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04578392, a NA study of Crohn Disease, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
NA
Development phase
181 participants
Enrollment target
7
Study locations

Study Summary

Study description - Patients will be randomized according to post-operative recurrence risk to either a high ligation of ileocolic artery or mesenteric sparing ileocolic resection for terminal ileal Crohn's disease. The primary endpoint 6-month endoscopic recurrence. Endpoints - Primary endpoint; 6 months Secondary endpoints at 1 and 5 years post ileocecal resection Study population - Adult Crohn's disease patients with medically refractory terminal ileal Crohn's disease undergoing a primary ileocecal resection. Study sites - Multicenter international study Description of study intervention - Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection Participate duration - 5 years

Primary Outcome

Endoscopic recurrence is define as a Rutgeert score \>2 at the time of colonoscopy The score is attributed directly, by selecting the appropriate degree - 5 degrees, from i0 (lowest) to i4 highest, with single-choice selection menu. Rutgeerts score is only be used for evaluation of post-surgical recurrences at ileocolic anastomosis level.

Conditions Studied

Interventions

  • PROCEDURE high ligation of ileocolic artery
  • PROCEDURE mesenteric sparing

Study Locations (7)

California

  • Cedars-Sinai Hospital System - Los Angeles
  • Stanford University School of Medicine - Stanford

Florida

  • Cleveland Clinic Florida - Weston

Ohio

  • Cleveland Clinic - Cleveland

Ontario

  • Mt. Sinai - Toronto

Milano

  • Humanitas - Rozzano

Middlesex

  • St Mark's Hospital and Academic Institution - Harrow

Trial Details

FieldValue
Enrollment Target 181 participants
Start Date 2020-07-28
Est. Completion 2027-12-31
Phase NA
The Cleveland Clinic

688 total trials

What NCT04578392 shows while recruiting

NCT04578392 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 203-participant average among 71 other Crohn Disease trials with a reported enrollment target (11% lower).

The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which high ligation of ileocolic artery is the first listed.

NCT04578392 lists 7 locations in 6 states (California, Florida, Ohio).

Frequently Asked Questions

What is clinical trial NCT04578392 about?

NCT04578392 is a clinical study titled "MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)". Study description - Patients will be randomized according to post-operative recurrence risk to either a high ligation of ileocolic artery or mesenteric sparing ileocolic resection for terminal ileal Crohn's disease. The primary endpoint 6-month endoscopic recurrence. Endpoints - Primary endpoint; 6...

What is the current status of trial NCT04578392?

This trial is currently recruiting. It is a NA study. The enrollment target is 181 participants. The study started on 2020-07-28. Estimated completion is 2027-12-31.

What conditions does trial NCT04578392 study?

This clinical trial studies the following conditions: Crohn Disease.

What interventions are being tested in trial NCT04578392?

The interventions under investigation include: high ligation of ileocolic artery (PROCEDURE), mesenteric sparing (PROCEDURE).

Who is sponsoring clinical trial NCT04578392?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04578392 being conducted?

This trial has 7 study locations across California, Florida, Ohio, Ontario, Milano. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04578392's enrollment target sits among peer trials

181 22nd of 71 higher than 50 of 71 other Crohn Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05597891 · 181 participants · NA

    Endovascular Engineering ENGULF Study

  • NCT03897998 · 182 participants · Phase 2

    Neural Correlates of Hypoalgesia Driven by Observation

  • NCT04300556 · 182 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  • NCT04323735 · 182 participants · Phase 2

    Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04578392, the US trial registry maintained by the National Library of Medicine. NCT04578392 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.